Licensing · Global (LMICs) · Announced 16 Nov 2026
Gilead Sciences → Ferozsons Laboratories
Gilead signed a royalty-free voluntary licence with Pakistan's Ferozsons Laboratories to manufacture and supply investigational obeldesivir for Ebola Bundibugyo post-exposure prophylaxis across 127 mainly low- and lower-middle-income countries.
Parties: Gilead Sciences (United States) → Ferozsons Laboratories (Pakistan)
- Deal type
- Licensing
- Value
- Royalty-free
- Territory
- 127 countries, primarily low- and lower-middle-income, including all African countries that have reported cases in the current Ebola Bundibugyo outbreak
- Therapeutic area
- Infectious Disease
- Asset
- obeldesivir
- Announced
- 16 Nov 2026
Our analysis
Why this matters
On 16 November 2026 Gilead Sciences announced royalty-free voluntary licences with Ferozsons Laboratories, Dr. Reddy's Laboratories and Eva Pharma for obeldesivir, an investigational oral antiviral being studied for post-exposure prophylaxis (PEP) of Ebola Bundibugyo virus disease (BVD). The licences cover 127 countries, primarily low- and lower-middle-income, including all African countries with reported cases in the current outbreak.
The agreements precede results from EBO-PEP, a partner-led Phase 3 randomised, placebo-controlled trial coordinated by ALIMA. Obeldesivir is not approved for any indication; supply under the licences requires supportive clinical data and regulatory authorisations.
The full analysis is free to read with a work email on this page.
Source: Gilead Sciences press release